Physician profile
Jessica L Bell
NPI 1659674463
$5,891.45
in general payments reported to CMS, 2019-2025
34 companies · $868 in 2025
The $868 reported for 2025 was more than what 84% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,501 · 2022: $921 · 2023: $1,160 · 2024: $1,442 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,469.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $756.29 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $727.42 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $716.44 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $605.52 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $528.16 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $404.72 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.59 | 2021-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.61 | 2021-2025 | Xifaxan |
| Exact Sciences Corporation | $186.30 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $179.45 | 2021 | |
| Dexcom, INC. | $165.95 | 2022-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.36 | 2023-2025 | Caplyta |
| Lundbeck LLC | $122.19 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $119.99 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $112.47 | 2021-2024 | Austedo Xr, Ajovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $91.45 | 2023-2025 | Rexulti, Abilify Maintena |
| Viatris Specialty LLC | $71.96 | 2025 | Yupelri |
| Biohaven Pharmaceutical Holding Company Ltd. | $62.82 | 2022 | |
| Merck Sharp & Dohme LLC | $43.11 | 2021-2023 | Steglatro, Belsomra |
| Pfizer INC. | $41.96 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $39.17 | 2025 | Zoryve |
| Axsome Therapeutics, INC. | $37.53 | 2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $37.22 | 2023-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $34.32 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $21.68 | 2024 | Recorlev |
| Vertex Pharmaceuticals Incorporated | $20.84 | 2025 | |
| Nestle Healthcare Nutrition INC. | $20.54 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.40 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $17.33 | 2023 | Quviviq |
| Astellas Pharma US INC | $16.62 | 2023 | Veozah |
| Mylan Specialty L.P. | $16.21 | 2022 | |
| Medtronic, INC. | $15.95 | 2021 | |
| Sumitomo Pharma America, INC. | $10.98 | 2023 | Gemtesa |
| Organon LLC | $9.90 | 2022-2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.